Clinical trial Recruiting at 1 site Observational Ages 20 to 65

Doxapram to improve diaphragm movement during spontaneous breathing trials in ventilated COPD patients

Official title: The Influence of Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial: a Prospective Observational Study

Run by Cairo University · NCT07022704 · Data updated 2026-11-12

This trial will test whether giving IV doxapram helps the diaphragm move more in people with moderate to severe COPD who are on a ventilator and doing a spontaneous breathing trial.

More COPD trials

Quick facts

Study typeObservational
Ages20 Years to 65 Years
SexAll
Enrollment35 (estimated)
SponsorCairo University
Academic / other
Locations1 site (Cairo, Cairo Governorate)
StatusRecruiting
StartedJune 22, 2025
Main results expectedOctober 30, 2025
Study endsNovember 1, 2025
Registry record updatedJune 26, 2025
Trial IDNCT07022704 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with moderate to severe COPD who are mechanically ventilated and undergoing a spontaneous breathing trial without allergy to doxapram and with an evaluable diaphragm on ultrasound.

Probably not a fit

Patients with neuromuscular disorders, a known allergy to doxapram, or when the diaphragm cannot be imaged are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center observational protocol in which intravenous doxapram is administered during spontaneous breathing trials in mechanically ventilated patients with moderate to severe COPD. Diaphragmatic excursion will be measured by an expert using respiratory muscle ultrasound before and after doxapram administration. Patients with doxapram allergy, neuromuscular disorders, or inability to visualize the diaphragm will be excluded. The study is conducted at Cairo University and collects physiologic ultrasound endpoints rather than clinical outcomes like weaning success.

Why it matters

Potential benefit: If successful, the findings could support using doxapram to enhance diaphragm movement and potentially help clinicians during weaning from mechanical ventilation.

How similar studies have gone: Respiratory stimulants like doxapram have historical use and mixed evidence for improving ventilation, but using doxapram specifically to increase diaphragmatic excursion during spontaneous breathing trials is relatively novel and not well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial

Exclusion Criteria:

* Refusal Allergy to doxapram neuromuscular disorders inability to evaluate the diaphragm

Where it's running

  • Cairo University
    Cairo, Cairo Governorate, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.